Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G M Oremek

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Anticancer Research|July 26, 2007
Value of tumour and inflammatory markers in lung cancerG M Oremek, H Sauer-Eppel, T H Bruzdziak
Anticancer Research|June 25, 2003
Diagnostic value of bone and tumour markers in patients with malignant diseasesG M Oremek, A Weis, N Sapoutzis, et al.
Anticancer Research|July 1, 1997
Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic diseaseG M Oremek, W Kramer, U B Seiffert, et al.
Transplantation Proceedings|February 6, 2007
Saphenous vein interposition as a salvage technique for complex vascular situations during renal transplantationA J Oertl, D Jonas, G M Oremek, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 15, 1995
[Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases]G M Oremek, U B Seiffert, R Siekmeier, et al.
Anticancer Research|June 25, 2003
Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathyG M Oremek, F Rutner, N Sapoutzis, et al.
Anticancer Research|August 30, 2008
Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinomaM Klepzig, H Sauer-Eppel, D Jonas, et al.
Anticancer Research|May 1, 2001
Value of tumor M2 (Tu M2-PK) in patients with renal carcinomaG M Oremek, N Sapoutzis, W Kramer, et al.
Anticancer Research|June 25, 2003
Tumor M2-PK levels in haematological malignanciesG M Oremek, St Rox, P Mitrou, et al.
Anticancer Research|September 2, 1999
The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinomaG M Oremek, S Teigelkamp, W Kramer, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Anticancer Research|July 26, 2007
Value of tumour and inflammatory markers in lung cancerG M Oremek, H Sauer-Eppel, T H Bruzdziak
Anticancer Research|June 25, 2003
Diagnostic value of bone and tumour markers in patients with malignant diseasesG M Oremek, A Weis, N Sapoutzis, et al.
Anticancer Research|July 1, 1997
Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic diseaseG M Oremek, W Kramer, U B Seiffert, et al.
Transplantation Proceedings|February 6, 2007
Saphenous vein interposition as a salvage technique for complex vascular situations during renal transplantationA J Oertl, D Jonas, G M Oremek, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 15, 1995
[Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases]G M Oremek, U B Seiffert, R Siekmeier, et al.
Anticancer Research|June 25, 2003
Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathyG M Oremek, F Rutner, N Sapoutzis, et al.
Anticancer Research|August 30, 2008
Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinomaM Klepzig, H Sauer-Eppel, D Jonas, et al.
Anticancer Research|May 1, 2001
Value of tumor M2 (Tu M2-PK) in patients with renal carcinomaG M Oremek, N Sapoutzis, W Kramer, et al.
Anticancer Research|June 25, 2003
Tumor M2-PK levels in haematological malignanciesG M Oremek, St Rox, P Mitrou, et al.
Anticancer Research|September 2, 1999
The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinomaG M Oremek, S Teigelkamp, W Kramer, et al.
Pageof 3